Clinical Trials Directory

Trials / Completed

CompletedNCT01354132

N-Acetyl-Cysteine (NAC) in Early Phase Schizophrenia Spectrum Psychosis

Effects of Oral N-Acetyl-Cysteine (NAC) in the Early Phase of Schizophrenia Spectrum Psychosis: Randomized, Parallel, Double- Blind, Placebo Controlled Trial

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
20 (actual)
Sponsor
Beth Israel Deaconess Medical Center · Academic / Other
Sex
All
Age
18 Years – 35 Years
Healthy volunteers
Not accepted

Summary

The investigators seek to examine the effect of add-on N-Acetyl-Cysteine (NAC) in the early phase of schizophrenia spectrum illness in collaboration with researchers Kim Do, PhD, and Philippe Conus, MD in Switzerland. Modifications of brain structure are thought to occur during the pre-illness phase and around the transition to psychosis. Therefore, studying new treatments that could target changes occurring during this period is of critical importance. Aims: Does add-on NAC treatment in early psychosis influence: * positive and negative symptoms * extrapyramidal side-effects of other medication * plasma concentration of glutathione * Mismatch Negativity, a physiological marker

Detailed description

The study proposes that a glutathione deficit leading to an abnormal response to oxidative stress is a vulnerability factor, combined with other brain specific factors, in brain functioning of some individuals with schizophrenia (Do et al., 2010). N-acetyl-cysteine is hypothesized to cross the blood-brain barrier and increase glutathione in the brain.

Conditions

Interventions

TypeNameDescription
DRUGn-acetylcysteine900 mg effervescent PharmaNAC tablet in water or juice: two tablets in the AM, one tablet in PM
DRUGPlaceboPlacebo tablets are placed in water or juice in the AM and PM

Timeline

Start date
2011-05-01
Primary completion
2014-08-01
Completion
2014-08-01
First posted
2011-05-16
Last updated
2017-07-05
Results posted
2017-06-07

Locations

2 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT01354132. Inclusion in this directory is not an endorsement.